DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the successful outcome of recent written and oral ...
The FDA should strengthen the evidence required for drug approvals under its accelerated pathway and increase transparency surrounding those regulatory decisions, according to a report (PDF) from a ...
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that ...
April 16 (Reuters) - The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical and ...
As explained in greater detail in our previous article, the accelerated approval program balances the urgent need for treatment of certain serious and/or rare conditions with the equally important ...
The US Food and Drug Administration (FDA) has finalized guidance to assist sponsors developing gene therapy products that incorporate genome editing (GE) of human somatic cells; the final version ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results